Investigational drug · Phase 2
ME-401
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Indolent B-cell Non-Hodgkin's Lymphoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
8
Any phase or sponsor naming "ME-401"
First trial start
2020
Sep 17, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ME-401", any sponsor or status.
Conditions studied
As listed on its trial records.
- Indolent B-cell Non-Hodgkin's Lymphoma
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "ME-401" as an intervention, largest first.
MEI Pharma, Inc.Industry
NCT03768505 · 169 participants · Start Jun 25, 2019 · Primary completion Mar 24, 2023
Drug: Zandelisib (ME-401) · For: Follicular Lymphoma (FL); Non Hodgkin Lymphoma; Marginal Zone Lymphoma
Sites: Tucson, Arizona; Anaheim, California; Beverly Hills, California · 115 sites in all
MEI Pharma, Inc.Industry
NCT02914938 · 97 participants · Start Oct 2016 · Primary completion Mar 29, 2023
Drug: ME-401; Rituximab and 1 more · For: Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL); Follicular Lymphoma (FL) and 4 more
Sites: Tucson, Arizona; Corona, California; Miami, Florida · 24 sites in all
- Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)Pivotal-lookingTerminated
MEI Pharma, Inc.Industry
NCT04745832 · 82 participants · Start Aug 13, 2021 · Primary completion Mar 20, 2023
Drug: Zandelisib; Rituximab and 2 more · For: Follicular Lymphoma (FL); Non Hodgkin Lymphoma; Marginal Zone Lymphoma
Sites: Tucson, Arizona; Fountain Valley, California; Long Beach, California · 141 sites in all
- Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)Active, not recruiting
Kyowa Kirin Co., Ltd.Industry
NCT04533581 · 61 participants · Start Sep 17, 2020 · Primary completion May 31, 2028
Drug: ME-401 · For: Indolent B-cell Non-Hodgkin's Lymphoma
Sites: Anjo, Japan; Nagoya, Japan; Kamogawa, Japan · 30 sites in all
- Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's LymphomaCompleted
Kyowa Kirin Co., Ltd.Industry
NCT03985189 · 14 participants · Start Apr 29, 2019 · Primary completion Jan 15, 2025
Drug: ME-401 · For: Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
Sites: Nagoya, Japan; Sapporo, Japan; Bunkyo-ku, Japan · 9 sites in all
Deepa JagadeeshAcademic, hospital or other
NCT04517435 · 13 participants · Start Apr 28, 2021 · Primary completion May 17, 2023
Drug: ME-401; Rituximab and 4 more · For: Diffuse Large B-Cell Lymphoma
Sites: Cleveland, Ohio
Jacob Soumerai, MDAcademic, hospital or other
NCT05604417 · 0 participants · Start Jan 2023 · Primary completion Dec 1, 2024
Drug: TAZEMETOSTAT; Zandelisib · For: Relapsed Follicular Lymphoma; Refractory Follicular Lymphoma
MEI Pharma, Inc.Industry
NCT05209308 · 0 participants · Start Nov 22, 2022 · Primary completion Mar 15, 2023
Drug: Zandelisib; Rituximab and 1 more · For: CLL
Sites: Boston, Massachusetts; Stony Brook, New York; Oklahoma City, Oklahoma · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A phase II study of zandelisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma: ME-401-K02 study.
Munakata W, Kumode T, Goto H, et al. · Br J Haematol 2025
- Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin's lymphoma: an open-label, multicenter, dose-escalation phase 1 study.
Goto H, Izutsu K, Ennishi D, et al. · Int J Hematol 2022
- Absorption, Distribution, and Binding Profile of ME-401, a Potent and Selective Oral Small-Molecule Inhibitor of Phosphatidylinositol 3-Kinase δ (PI3Kδ) in Animal and B-Cell Lymphoma Models.
Moreno O, Wood J · Target Oncol 2019
- Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia.
Patel K, Pagel JM · Curr Hematol Malig Rep 2019
- Safety, Pharmacokinetics, and Pharmacodynamics of ME-401, an Oral, Potent, and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Following Single Ascending Dose Administration to Healthy Volunteers.
Moreno O, Butler T, Zann V, et al. · Clin Ther 2018
- Vapor resection: a good alternative to standard loop resection in the management of prostates >40 cc.
Gupta NP, Doddamani D, Aron M, et al. · J Endourol 2002
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.